Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Cash T, Marachelian A, DuBois SG, Chi YY, Baregamyan A, Groshen SG, Jonus HC, Shamirian A, Crowley M, Goodarzian F, Acharya PT, Pawel B, Erbe AK, Shahi A, Zaborek J, Kennedy E, Asgharzadeh S, Villablanca JG, Pinto N, Weiss BD, Mosse YP, Desai AV, Macy ME, Granger M, Vo KT, Sondel PM, Matthay KK, Park JR, Goldsmith KC

Open source

DOI: 10.1200/jco-24-02612
Published: 2025 Aug
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-24-02612,
  title = {Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.},
  author = {Cash T and Marachelian A and DuBois SG and Chi YY and Baregamyan A and Groshen SG and Jonus HC and Shamirian A and Crowley M and Goodarzian F and Acharya PT and Pawel B and Erbe AK and Shahi A and Zaborek J and Kennedy E and Asgharzadeh S and Villablanca JG and Pinto N and Weiss BD and Mosse YP and Desai AV and Macy ME and Granger M and Vo KT and Sondel PM and Matthay KK and Park JR and Goldsmith KC},
  year = {2025},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-24-02612},
  url = {https://doi.org/10.1200/jco-24-02612}
}

RIS

TY  - JOUR
TI  - Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
AU  - Cash T
AU  - Marachelian A
AU  - DuBois SG
AU  - Chi YY
AU  - Baregamyan A
AU  - Groshen SG
AU  - Jonus HC
AU  - Shamirian A
AU  - Crowley M
AU  - Goodarzian F
AU  - Acharya PT
AU  - Pawel B
AU  - Erbe AK
AU  - Shahi A
AU  - Zaborek J
AU  - Kennedy E
AU  - Asgharzadeh S
AU  - Villablanca JG
AU  - Pinto N
AU  - Weiss BD
AU  - Mosse YP
AU  - Desai AV
AU  - Macy ME
AU  - Granger M
AU  - Vo KT
AU  - Sondel PM
AU  - Matthay KK
AU  - Park JR
AU  - Goldsmith KC
PY  - 2025
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-24-02612
UR  - https://doi.org/10.1200/jco-24-02612
ER  -

APA

T, C., A, M., SG, D., YY, C., A, B., SG, G., HC, J., A, S., M, C., F, G., PT, A., B, P., AK, E., A, S., J, Z., E, K., S, A., JG, V., N, P., BD, W., YP, M., AV, D., ME, M., M, G., KT, V., PM, S., KK, M., JR, P., & KC, G. (2025). Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-24-02612

Source records

pubmed · retrieved 2026-09-26T06:54:32.976Z